OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Study details:
This is an international, multicenter, randomized, open-label, active-controlled, phase 3 clinical trial. The purpose of this trial is to compare the safety and efficacy of palazestrant (OP-1250) as a single agent to the standard of care endocrine therapy: either fulvestrant or an aromatase inhibitor (anastrozole, letrozole, or exemestane). This trial is seeking adult participants with ER+, HER2- advanced or metastatic breast cancer whose disease has relapsed or progressed on 1 or 2 prior lines of standard-of-care endocrine therapy for metastatic breast cancer.
Prior lines of therapy must include one line of endocrine therapy in combination with a CDK 4/6 inhibitor. In the dose-selection part of the trial, approximately 120 participants will be randomized to one of the two doses of palazestrant or to the standard-of-care endocrine therapy. Thereafter, approximately 390 participants will be randomized to palazestrant at the selected dose or to the standard-of-care endocrine therapy.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
- Adult female or male participants.
- ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy.
- Evaluable disease (measurable disease or bone-only disease).
- Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate hematologic, hepatic, and renal functions.
- Female participants can be pre-, peri- or postmenopausal.
- Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.
Exclusion criteria
- Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy.
- Previously received chemotherapy in the advanced/metastatic setting.
- Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy.
- History of allergic reactions to study treatment.
- Any contraindications to the selected standard-of-care endocrine therapy in the local prescribing information.
- Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment.
- Clinically significant comorbidities such as significant cardiac or cerebrovascular disease, gastrointestinal disorders that could affect absorption of study treatment.
Eligibility
Age eligible for study : NA
Healthy volunteers accepted : No
Gender eligible for study: ALL
Things to know
Study dates
Study start:
Primary completion:
Study completion finish:
Study type
TREATMENT
Phase
- PHASE3
Study ID
NCT06016738
Intervention or treatment
DRUG: Palazestrant
DRUG: Fulvestrant
DRUG: Anastrozole
DRUG: Letrozole
DRUG: Exemestane
Conditions
- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- ER Positive Breast Cancer
- HER2 Negative Breast Carcinoma
You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.
Research sites nearby
Closest Location:
Clinical Trial Site
Select from list below to view details:
Clinical Trial Site
Gosford, New South Wales, Australia
Clinical Trial Site
Westmead, New South Wales, Australia
Clinical Trial Site
Adelaide, South Australia, Australia
Clinical Trial Site
Ballarat Central, Victoria, Australia
Loading map...
Who is running the clinical trial?
Olema Pharmaceuticals, Inc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: Palazestrant (OP-1250)
| Drug: Palazestrant |
ACTIVE_COMPARATOR: Standard of Care Endocrine Therapy
| Drug: Fulvestrant, Drug: Anastrozole, Drug: Letrozole, Drug: Exemestane |
What is the study measuring?
Primary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Dose-Selection Part: Incidence of adverse events | To evaluate the number of participants with adverse events | From Date of Randomization up to 16 weeks |
| Dose-Selection Part: Incidence of dose reduction | To evaluate the number of participants reducing the dose of palazestrant | From Date of Randomization up to 16 weeks |
| Dose-Selection Part: Incidence of drug discontinuation | To evaluate the number of participants discontinuing palazestrant | From Date of Randomization up to 16 weeks |
| Trial: Progression-Free Survival (PFS) | To compare PFS, based on a Blinded Independent Review Committee (BIRC) assessment, between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1-mutation detected and ESR1-mutation not detected participants. | From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 2 years) |
Secondary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Trial: Overall Survival (OS) | To compare OS between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1 mutation detected and ESR1 mutation not detected participants. | From Date of Randomization until Death Due to Any Cause (estimated as up to 4 years) |
References
Clinical Trials Gov: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerOther trials to consider
Loading suggested trials...